Archive
559 articles, sorted by publication time.
Comp2Comp has released two FDA 510(k)-cleared CT analysis models and external validation data, adding a layer of transparency to opportunistic screening for abdominal aortic aneurysm and osteoporosis risk, while also laying out some of the hardest questions hospitals face before adopting AI.
As official recommendations shift back and forth, vaccination during pregnancy is no longer just a reminder sheet in the exam room, but a stress test of how medical professionals maintain public trust.
A University of Calgary team reports in mouse models that a tumor-intrinsic program driven by NOTUM may allow the most common form of colorectal cancer, and the one least responsive to immunotherapy, to evade attack; this remains preclinical research, but it shifts the focus of drug resistance from immune cells themselves back to how cancer cells hide.
Treating chronic liver disease is not only about finding the right target, but also about controlling how long the signal lasts. A Nature study shifts FXR agonists from long-duration exposure toward brief pulses, but the true clinical weight still needs to be answered by late-stage trials.
A three-generation mouse study shows that methylation marks on DNA can sometimes move in ways that do not follow classical rules of inheritance, even appearing in offspring when they are not seen in the parents, leaving deeper questions about the relationship between environment, development, and heredity.
GLP-1 drugs have reshaped expectations for obesity treatment, but a new commentary cautions that the real turning point may not lie in a single miracle drug, but in how medications, endoscopy, surgery, and precision medicine are carefully arranged into long-term care.
Terpenes were originally the chemical backdrop of plant aromas. Now, in mouse models of post-surgical pain and fibromyalgia, they are showing analgesic potential; they remain far from becoming clinical drugs, but they offer an early clue distinct from THC and opioids.
EXO1 is normally a molecular scissor that maintains the genome, but in excess it can cut newly formed DNA; the finding brings some tumors without BRCA defects into the scope of reassessment with existing drugs.
A study following infants and young children links cord-blood methylation, gut microbiota in the first year, and behavioral scales at age three; it suggests that autism and ADHD risk may not follow a single pathway, but may gradually take shape across gene regulation, immunity, and microbes.
A phase 3 clinical trial has brought pancreatic cancer’s most difficult molecular switch into treatable range; the results are encouraging, but approval, accessibility, and drug resistance issues are only just beginning to face their real test.
GLP-1 drugs have reshaped diabetes and weight-loss treatment, but a study spanning human, animal, and clinical trial data offers a reminder: differences in efficacy may not be only a matter of willpower or dose, but may also lie in genes that regulate incretin signaling.
This early trial pushes the vaccine strategy from “chasing variants with updates” toward a defense aimed at an entire virus family; immune responses have been observed, but true protection still awaits answers from larger studies.